Biotechnology started with the DNA sequencing breakthroughs, the human genome project and cloning/designing cellular organisms. Now, in the light of ever more ground-breaking technology, the SCI Biotechnology Interest Group provides a forum for this industry sector. Its first major event will bring together advances in precision medicine - a concept that seeks to discover/design drugs that deliver a more individual approach to disease management.
Biotechnology is providing new solutions in this area and speakers from both academia and industry will cover the major themes of advances in biopharmaceuticals, AI, gene editing, protein design and drug development - from the molecular level of proteins and DNA through genomes and cells to disease models and therapeutic interventions.
The meeting will also provide networking opportunities for all those with an interest in bringing together biosciences and technology in this important initiative.
|09.00||Registration and refreshments|
|09.35||The impact of AI on drug discovery
Dr Georgia McGaughey, Vertex
|10.15||Phenotypic screening in iPSC-derived neurons - a new paradigm in drug discovery
Dr Sandra Lubitz, Evotec
|11.15||ANN based methods for discovery of biomarkers, phenotypic drivers and drug targets - a cancer case study
Prof Graham Ball, Nottingham Trent University
|11.45||Precise genome editing: Applying CRISPR in drug discovery
David Fisher, AstraZeneca
|12.15||Developing bicycle toxin conjugates to target cancerous tumours'
Gemma Mudd, Bicycle Therapeutics
|12.45||Lunch and exhibition|
|13.45||Strategies to target protein-protein interactions
Marta Westwood, UCB
|14.15||Inhalation dosing - targeted delivery of respiratory therapeutics
Andrew Carr, Charles River
|14.45||Biologics Plenary: Delivering innovation in Biotechnology: Experiences and learning from the last 15 years
Graham Hillier, CPI
|15.55||Development of engineered biocatalysts for the synthesis of pharmaceuticals
Prof Nick Turner, University of Manchester
|16.25||Industrial application of imine reductases for biocatalytic reductive amination
Dr Markus Schober, GSK
|17.30||Networking and refreshments|
Tel: +44 (0)20 7598 1561
Early bird fees before Friday 1 March 2019
|£100||SCI Member/ ONE Nucleus member/ OBN Member|
|£40||SCI Student Member|
Standard fees after Friday 1 March 2019
|£120||SCI Member/ ONE Nucleus member/ OBN Member|
|£50||SCI Student Member|
You must sign up for membership to join this event. FREE membership options available.
SCI Members attending this meeting are able to claim CPD points.
Anyone wishing to present a poster should submit a one-page abstract to email@example.com by Friday 15 March 2019 with "Targeted medicine: new solutions from biotechnology - poster abstract" in the subject line. Selected poster presenters will be given the opportunity to give a flash presentation.
An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email firstname.lastname@example.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.
Become an SCI Member to receive events discounts